SBFMW (Sunshine Biopharma) Net Issuance of Debt : $-0.12 Mil (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sunshine Biopharma Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Sunshine Biopharma's net issuance of debt for the three months ended in Jun. 2024 was $-0.03 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.12 Mil.

Sunshine Biopharma Net Issuance of Debt Historical Data

The historical data trend for Sunshine Biopharma's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Net Issuance of Debt Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

0.42

1.61

2.91

-1.93

-0.13

Sunshine Biopharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Net Issuance of Debt	Get a 7-Day Free Trial															-0.03	-0.03	-0.03	-0.03	-0.03

Sunshine Biopharma Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

Sunshine Biopharma Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

SBFM:USA

Address

1177 Avenue of the Americas, 5th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.